#United States #AstraZeneca #San Mateo #Helix #GenoSphere

Helix and AstraZeneca: A New Era in Genomic Research

In a significant step forward for genomic research, Helix, a leader in enterprise genomics, has officially announced a multi-year partnership with AstraZeneca, a renowned global biopharmaceutical company. This collaboration aims to enhance drug discovery and development by leveraging Helix's cutting-edge genomic resources.

What is the GenoSphere™?

At the core of this collaboration is Helix's GenoSphere™, a database composed of well-characterized cohorts that encompass comprehensive genomic data and longitudinal clinical insights. This platform aims to facilitate Life Sciences research across various stages of the drug development process. One of the primary benefits of the GenoSphere cohort is that it holds de-identified datasets housed in the Helix Research Network®, North America's largest precision health network.

Advantageous Data Access for AstraZeneca

Through this partnership, AstraZeneca will gain access to Helix's ever-expanding research database, which features detailed genomic information from Exome+ sequencing. This sophisticated genomic profiling offers insights into thousands of genes and variants that could influence the understanding of numerous disease areas, including cardiometabolic disorders, respiratory issues, autoimmune diseases, and more.

The GenoSphere™ cohorts are not just about genomic data; they are enriched with longitudinal clinical records that encompass an average electronic health record (EHR) history of 13 years. This data includes medical diagnoses, lab results, and a host of other critical information that evolves over the patient's journey, allowing for real-time insights.

Enhancing Research Capabilities

The collaboration emphasizes the increasing importance of utilizing large-scale clinico-genomic data as an essential resource for advancing biomedical research. According to James Lu, M.D., Ph.D., CEO and co-founder of Helix, this partnership marks a pivotal moment where “comprehensive genomic data combined with rich longitudinal clinical information can help accelerate research efforts, deepen disease understanding, and promote the development of targeted therapies.”

The fully consented nature of the cohort will allow for accelerated follow-on studies, enabling researchers to gather necessary insights swiftly and efficiently.

Looking Ahead

As this collaboration progresses, it will be fascinating to see how the integration of Helix's genomic data with AstraZeneca’s drug development strategies will transform current scientific approaches to treating various health conditions. This partnership reflects a broader trend toward precision medicine, where understanding individual genetic profiles can pave the way for more effective, personalized treatment options.

For further insights about this partnership, the GenoSphere cohort, and possible collaborative opportunities, both organizations encourage industry peers to connect and engage through Helix’s official channels.

About Helix

Helix represents a leading force in the field of genomics, driving health systems to utilize genomic data effectively across their platforms. Committed to transforming healthcare through the application of genomic science, Helix continues to push the boundaries of what is possible, turning groundbreaking research into real-world clinical impacts. For more information about their innovative approaches, visit www.helix.com.